XLO
|Xilio Development Inc
NASDAQ
USD 0.69
-0.01|-1.00%
Current Price
USD 0.69
Change
USD -0.01 (-1.00%)
P/E Ratio
Dividend Yield
Market Cap
48.51M
Volume
417,249
Open
USD 0.69
Previous Close
USD 0.70
52-Week High
USD 1.70
52-Week Low
USD 0.62
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Rene Russo BCPS, Pharm.D.
Employees:64
Headquarters:Waltham, USA
Website:xiliotx.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions